Category:BGT Ferumoxytol(B38311)
From BiomedGT
BGT_Ferumoxytol(B38311)
Lexical
Concept Code: B38311
(O)
Preferred Name: Ferumoxytol
Coding Scheme: BGT (09.06a )
Synonym: Ferumoxytol (PT) (Source: NCI)
Definition: A superparamagnetic iron oxide nanoparticle coated with a low molecular weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl ether, with potential anti-anemic and imaging properties. After intravenous administration, ferumoxytol replaces iron stores with fewer side effects compared to the use of oral iron. In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravasculature for a prolonged period and so may be used as a blood pool agent. (NCI05) (Source: NCI)
Scope Note: Iron Replacement Agent
URI: http://ncicb.nci.nih.gov/xml/owl/EVS/BiomedGT.owl#B38311
Properties
Semantic_Type: Pharmacologic Substance
Def_Curator: NCI Drug Dictionary
UMLS_CUI: C1453192
NSC_Code: 729745
PDQ_Open_Trial_Search_ID: 377345
PDQ_Closed_Trial_Search_ID: 377345
Associations
Parent: Contrast_Agent (primitive)
Form:LexWiki_BGT_Form
| BGT Concept Type(P365) | O + |
| BGT Def Curator(P318) | NCI Drug Dictionary + |
| BGT NSC Code(P175) | 729745 +info.pngNSC Code lookup |
| BGT PDQ Closed Trial Search ID(P330) | 377345 +info.pngPDQ Closed Trial Search |
| BGT PDQ Open Trial Search ID(P329) | 377345 +info.pngPDQ Open Trial Search |
| BGT Semantic Type(P106) | Pharmacologic Substance +info.pngSemantic Type lookup |
| BGT Synonym(P104) | Ferumoxytol + |
| BGT UMLS CUI(P207) | C1453192 +info.pngUMLS_CUI_lookup |
| DCTerms hasVersion(hasVersion) | BGT/Versions/09.06a + |
| Has default form | LexWiki BGT Form + |
| LexWiki Concept Code | B38311 + |
| LexWiki Definition | A superparamagnetic iron oxide nanoparticl … A superparamagnetic iron oxide nanoparticle coated with a low molecular weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl ether, with potential anti-anemic and imaging properties. After intravenous administration, ferumoxytol replaces iron stores with fewer side effects compared to the use of oral iron. In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravasculature for a prolonged period and so may be used as a blood pool agent. (NCI05) (Source: NCI) a blood pool agent. (NCI05) (Source: NCI) |
| LexWiki Preferred Name | Ferumoxytol + |
| LexWiki URI | http://ncicb.nci.nih.gov/xml/owl/EVS/BiomedGT.owl#B38311 + |
| SKOS inScheme(inScheme) | BGT + |
| SKOS scopeNote(scopeNote) | Iron Replacement Agent |
This category currently contains no articles or media.
